Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA.

Mol Ther · 2021 · PMC7935664 · PMID 33352107

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

We observed that co-formulation of ruxolitinib with saRNA did not have any effect on the percentage of EGFP + cells ( Figure 4 C), although there was a slight trend that increasing the dose of ruxolitinib actually decreased the percentage of EGFP + cells from ∼8% to ∼5%.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.